← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Eli Lilly LLY $1.12T	3,665	+94	+3%	$687B
2	2 Pfizer PFE $168B	2,917	+36	+1%	$109B
3	3 Amgen AMGN $235B	2,830	+39	+1%	$133B
4	4 Novo Nordisk NVO $173B	1,787	-78	-4%	$39.7B
5	5 Becton Dickinson BDX $52.8B	1,579	-9	-0.6%	$62B
6	6 McKesson MCK $116B	1,549	-86	-5%	$54.2B
7	7 Regeneron Pharmaceuticals REGN $82B	1,392	+57	+4%	$97.5B
8	8 AstraZeneca AZN $259B	1,231	+18	+1%	$39.1B
9	9 Conagra Brands CAG $6.77B	873	+1	+0.1%	$13.2B
10	10 ResMed RMD $34.1B	802	+29	+4%	$21.3B
11	11 West Pharmaceutical WST $27B	730	-47	-6%	$20.5B
12	12 Lamb Weston LW $7.47B	687	-68	-9%	$8.45B
13	13 DaVita DVA $12.1B	601	+40	+7%	$12.2B
14	14 Teva Pharmaceutical Industries Limited TEVA $47.9B	544	+10	+2%	$11.3B
15	15 DELISTED CATALENT, INC. CTLT	470	+22	+5%	$10.8B
16	16 BellRing Brands BRBR $1.05B	450	+3	+0.7%	$7.33B
17	17 Viking Therapeutics VKTX $3.48B	422	+35	+9%	$5.25B
18	18 DELISTED WK Kellogg Co KLG	378	-12	-3%	$1.27B
19	19 Embecta EMBC $365M	367	+5	+1%	$771M
20	20 Inspire Medical Systems INSP $2.03B	346	+21	+6%	$7.03B
21	21 Hims & Hers Health HIMS $6.85B	309	+11	+4%	$2.54B
22	22 Amphastar Pharmaceuticals AMPH $1.12B	279	+10	+4%	$1.72B
23	23 Madrigal Pharmaceuticals MDGL $10.6B	257	0	0%	$4.77B
24	24 Biohaven BHVN $1.73B	254	+29	+13%	$4.31B
25	25 Opko Health OPK $1.2B	234	+2	+0.9%	$279M